Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation

BioFactors

Volumn 34, Issue 4, 2008, Pages 313-329

  Morceau, Franck ^a   Buck, Isabelle ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Bcr Abl; Erythroid genes; Hsp90; P38MAPK; PU.1; Radicicol

Indexed keywords

BCR ABL PROTEIN; BETA ACTIN; CD11B ANTIGEN; ERYTHROCYTE BAND 3 PROTEIN; ERYTHROID ASSOCIATED FACTOR; ERYTHROPOIETIN RECEPTOR; FIBRINOGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPHORIN A; HEAT SHOCK PROTEIN 90; HEMOGLOBIN A1C; HEMOGLOBIN GAMMA 1; HYDROXYMETHYLBILAN SYNTHASE; IMATINIB; IMMUNOGLOBULIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PROTEIN TYROSINE KINASE; RADICICOL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOG1; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR SP1; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ERYTHROCYTE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CELL DIFFERENTIATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION; HUMANS; K562 CELLS; MACROLIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS;

EID: 76449118324     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520340407     Document Type: Conference Paper

References (67)

1. W. Aerbajinai, J. Zhu, Z. Gao, K. Chin and G.P. Rodgers, Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis, Blood 110 (2007), 2864-2871.
2. M. Anafi, A. Gazit, A. Zehavi, Y. Ben-Neriah and A. Levitzki, Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate, Blood 82 (1993), 3524-3529.
3. N.C. Andrews, H. Erdjument-Bromage, M.B. Davidson, P. Tempst and S.H. Orkin, Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein, Nature 362 (1993), 722-728.
4. P.D. Aplan, K. Nakahara, S.H. Orkin and I.R. Kirsch, The SCL gene product: a positive regulator of erythroid differentiation, Embo J 11 (1992), 4073-4081.
5. G.A. Blobel, T. Nakajima, R. Eckner,M. Montminy and S.H. Orkin, CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation, Proc Natl Acad Sci USA 95 (1998), 2061-2066.
6. M. Broemer, D. Krappmann and C. Scheidereit, Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation, Oncogene 23 (2004), 5378-5386.
7. A. Brozik, N.P. Casey, C. Hegedus, A. Bors, A. Kozma, H. Andrikovics, M. Geiszt, K. Nemet and M. Magocsi, Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK, Ann N Y Acad Sci 1090 (2006), 344-354.
8. I. Buck, F. Morceau, S. Cristofanon, C. Heintz, S. Chateauvieux, S. Reuter, M. Dicato and M. Diederich, Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation, Biochem Pharmacol 76 (2008), 1229-1239.
9. I. Buck, F. Morceau, C. Grigorakaki, M. Dicato and M. Diederich, Linking anemia to inflammation and cancer: The crucial role of TNFalpha, Biochem Pharmacol (2009).
10. P.E. Burger, E.B. Dowdle, P.T. Lukey and E.L. Wilson, Basic fibroblast growth factor antagonizes transforming growth factor beta-mediated erythroid differentiation in K562 cells, Blood 83 (1994), 1808-1812.
11. B. Calabretta and D. Perrotti, The biology of CML blast crisis, Blood 103 (2004), 4010-4022.
12. A.B. Cantor and S.H. Orkin, Transcriptional regulation of erythropoiesis: an affair involving multiple partners, Oncogene 21 (2002), 3368-3376.
13. M.F. Clarke, J.F. Kukowska-Latallo, E. Westin, M. Smith and E.V. Prochownik, Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation, Mol Cell Biol 8 (1988), 884-892.
14. S.N. Constantinescu, S. Ghaffari and H.F. Lodish, The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction, Trends Endocrinol Metab 10 (1999), 18-23.
15. J.D. Crispino, M.B. Lodish, J.P. MacKay and S.H. Orkin, Use of altered specificity mutants to probe a specific proteinprotein interaction in differentiation: the GATA-1:FOG complex, Mol Cell 3 (1999), 219-228.
16. P. Delmotte and J. Delmotte-Plaque, A new antifungal substance of fungal origin, Nature 171 (1953), 344.
17. C. Dong, R.J. Davis and R.A. Flavell, MAP kinases in the immune response, Annu Rev Immunol 20 (2002), 55-72.
18. N.J. Elwood, H. Zogos, D.S. Pereira, J.E. Dick and C.G. Begley, Enhanced megakaryocyte and erythroid development from normal human CD34(+) cells: consequence of enforced expression of SCL, Blood 91 (1998), 3756-3765.
19. J.R. Evans, S.A. Mitchell, K.A. Spriggs, J. Ostrowski, K. Bomsztyk, D. Ostarek and A.E. Willis, Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo, Oncogene 22 (2003), 8012-8020.
20. R. Ferreira, K. Ohneda, M. Yamamoto and S. Philipsen, GATA1 function, a paradigm for transcription factors in hematopoiesis, Mol Cell Biol 25 (2005), 1215-1227.
21. Y. Fujiwara, A.N. Chang, A.M. Williams and S.H. Orkin, Functional overlap of GATA-1 and GATA-2 in primitive hematopoietic development, Blood 103 (2004), 583-585.
22. V. Gopal, P. Kadam, H. Preisler, B. Hulette, Y.Q. Li, P. Steele, J. Freeman and S. Banavali, Abnormal regulation of the myc gene in myeloid leukemia, Med Oncol Tumor Pharmacother 9 (1992), 139-147.
23. J.A. Grass, H. Jing, S.I. Kim, M.L. Martowicz, S. Pal, G.A. Blobel and E.H. Bresnick, Distinct functions of dispersed GATA factor complexes at an endogenous gene locus, Mol Cell Biol 26 (2006), 7056-7067.
24. A. Hernandez-Hernandez, P. Ray, G. Litos, M. Ciro, S. Ottolenghi, H. Beug and J. Boyes, Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1, Embo J 25 (2006), 3264-3274.
25. D. Hodge, E. Coghill, J. Keys, T. Maguire, B. Hartmann, A. McDowall, M. Weiss, S. Grimmond and A. Perkins, A global role for EKLF in definitive and primitive erythropoiesis, Blood 107 (2006), 3359-3370.
26. Y. Honma, J. Okabe-Kado, M. Hozumi, Y. Uehara and S. Mizuno, Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity, Cancer Res 49 (1989), 331-334.
27. Y. Honma, J. Okabe-Kado, T. Kasukabe, M. Hozumi and K. Umezawa, Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells, Jpn J Cancer Res 81 (1990), 1132-1136.
28. S. Huang, Y. Qiu, Y. Shi, Z. Xu and S.J. Brandt, P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL, Embo J 19 (2000), 6792-6803.
29. J. Jiang, S. Best, S. Menzel, N. Silver, M.I. Lai, G.L. Surdulescu, T.D. Spector and S.L. Thein, cMYB is involved in the regulation of fetal hemoglobin production in adults, Blood 108 (2006), 1077-1083.
30. K. Kohmura, Y. Miyakawa, Y. Kawai, Y. Ikeda and M. Kizaki, Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells, J Cell Physiol 198 (2004), 370-376.
31. K. Kuzelova, D. Grebenova, I. Marinov and Z. Hrkal, Fast apoptosis and erythroid differentiation induced by imatinib mesylate in JURL-MK1 cells, J Cell Biochem 95 (2005), 268-280.
32. J.J. Liu, S.C. Hou and C.K. Shen, Erythroid gene suppression by NF-kappa B, J Biol Chem 278 (2003), 19534-19540.
33. A. Maloney and P. Workman, HSP90 as a new therapeutic target for cancer therapy: the story unfolds, Expert Opin Biol Ther 2 (2002), 3-24.
34. M. Merika and S.H. Orkin, Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF, Mol Cell Biol 15 (1995), 2437-2447.
35. M.A. Moosavi, R. Yazdanparast and A. Lotfi, ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5'-triphosphate-mediated terminal erythroid differentiation of K562 cells, Int J Biochem Cell Biol 39 (2007), 1685-1697
36. F. Morceau, B. Chenais, R. Gillet, J.C. Jardillier, P. Jeannesson and C. Trentesaux, Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells, Cell Growth Differ 7 (1996), 1023-1029.
37. F. Morceau, C. Dupont, V. Palissot, P. Borde-Chiche, C. Trentesaux, M. Dicato and M. Diederich, GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the gamma-globin mRNA, Leukemia 14 (2000), 1589-1597.
38. F. Morceau, M. Schnekenburger, R. Blasius, I. Buck, M. Dicato and M. Diederich, Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1, Cancer Lett 240 (2006), 203-212.
39. F. Morceau, M. Schnekenburger, M. Dicato and M. Diederich, GATA-1: friends, brothers, and coworkers, Ann N Y Acad Sci 1030 (2004), 537-554.
40. M. Notari, P. Neviani, R. Santhanam, B.W. Blaser, J.S. Chang, A. Galietta, A.E. Willis, D.C. Roy, M.A. Caligiuri, G. Marcucci and D. Perrotti, A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation, Blood 107 (2006), 2507-2516.
41. J.I. Park, H.S. Choi, J.S. Jeong, J.Y. Han and I.H. Kim, Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells, Cell Growth Differ 12 (2001), 481-486.
42. S. Parmar, E. Katsoulidis, A. Verma, Y. Li, A. Sassano, L. Lal, B. Majchrzak, F. Ravandi, M.S. Tallman, E.N. Fish and L.C. Platanias, Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells, J Biol Chem 279 (2004), 25345-25352.
43. C. Peng, D. Li and S. Li, Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors, Cell Cycle 6 (2007), 2227-2231.
44. L.C. Platanias, Map kinase signaling pathways and hematologic malignancies, Blood 101 (2003), 4667-4679.
45. L.C. Platanias, The p38 mitogen-activated protein kinase pathway and its role in interferon signaling, Pharmacol Ther 98 (2003), 129-142.
46. M.V. Powers and P. Workman, Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors, Endocr Relat Cancer 13(Suppl 1) (2006), S125-135.
47. N. Rekhtman, F. Radparvar, T. Evans and A.I. Skoultchi, Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells, Genes Dev 13 (1999), 1398-1411.
48. K. Sawafuji, Y. Miyakawa,M. Kizaki and Y. Ikeda, Cyclosporin A induces erythroid differentiation of K562 cells through p38 MAPK and ERK pathways, Am J Hematol 72 (2003), 67-69.
49. C.L. Sawyers, Chronic myeloid leukemia, N Engl J Med 340 (1999), 1330-1340.
50. C.L. Sawyers,W. Callahan and O.N.Witte, Dominant negative MYC blocks transformation by ABL oncogenes, Cell 70 (1992), 901-910.
51. H.J. Schaeffer and M.J. Weber, Mitogen-activated protein kinases: specific messages from ubiquitous messengers, Mol Cell Biol 19 (1999), 2435-2444.
52. R.C. Schnur, M.L. Corman, R.J. Gallaschun, B.A. Cooper, M.F. Dee, J.L. Doty, M.L. Muzzi, C.I. DiOrio, E.G. Barbacci, P.E. Miller et al., erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structureactivity relationships, J Med Chem 38 (1995), 3813-3820.
53. R.C. Schnur, M.L. Corman, R.J. Gallaschun, B.A. Cooper, M.F. Dee, J.L. Doty, M.L. Muzzi, J.D. Moyer, C.I. DiOrio, E.G. Barbacci et al., Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives, J Med Chem 38 (1995), 3806-3812.
54. E. Schreiber, P. Matthias, M.M. Muller andW. Schaffner, Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells, Nucleic Acids Res 17 (1989), 6419.
55. T.W. Schulte, S. Akinaga, S. Soga, W. Sullivan, B. Stensgard, D. Toft and L.M. Neckers, Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin, Cell Stress Chaperones 3 (1998), 100-108.
56. S.V. Sharma, T. Agatsuma and H. Nakano, Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol, Oncogene 16 (1998), 2639-2645.
57. Y. Shiotsu, L.M. Neckers, I.Wortman, W.G. An, T.W. Schulte, S. Soga, C. Murakata, T. Tamaoki and S. Akinaga, Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex, Blood 96 (2000), 2284-2291.
58. R.A. Shivdasani and S.H. Orkin, Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2, Proc Natl Acad Sci U S A 92 (1995), 8690-8694.
59. S. Soga, T. Kozawa, H. Narumi, S. Akinaga, K. Irie, K. Matsumoto, S.V. Sharma, H. Nakano, T. Mizukami and M. Hara, Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway, J Biol Chem 273 (1998), 822-828.
60. L.S. Steelman, S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand and J.A. McCubrey, JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis, Leukemia 18 (2004), 189-218.
61. J.G. Supko, R.L. Hickman, M.R. Grever and L. Malspeis, Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent, Cancer Chemother Pharmacol 36 (1995), 305-315.
62. K. Tago, F. Tsukahara, M. Naruse, T. Yoshioka and K. Takano, Hsp90 inhibitors attenuate effect of dexamethasone on activated NF-kappaB and AP-1, Life Sci 74 (2004), 1981-1992.
63. S. Uddin, J. Ah-Kang, J. Ulaszek, D. Mahmud and A.Wickrema, Differentiation stage-specific activation of p38 mitogenactivated protein kinase isoforms in primary human erythroid cells, Proc Natl Acad Sci USA 101 (2004), 147-152.
64. L. Whitesell and S.L. Lindquist, HSP90 and the chaperoning of cancer, Nat Rev Cancer 5 (2005), 761-772.
65. O. Witt, K. Sand and A. Pekrun, Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways, Blood 95 (2000), 2391-2396.
66. M.Y. Zhang, S.C. Sun, L. Bell and B.A. Miller, NF-kappaB transcription factors are involved in normal erythropoiesis, Blood 91 (1998), 4136-4144.
67. P. Zhang, X. Zhang, A. Iwama, C. Yu, K.A. Smith, B.U. Mueller, S. Narravula, B.E. Torbett, S.H. Orkin and D.G. Tenen, PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding, Blood 96 (2000), 2641-2648.